The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections to treat several inflammatory conditions. Adults and certain children can receive this medication to treat ...

Credit: Novartis The IV formulation is supplied as a 125mg/5mL solution in a single-dose vial and requires dilution prior to administration. The Food and Drug Administration (FDA) has approved an ...

The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, according to a press ...

Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA’s approval of Cosentyx was the most read Healio ...

Please note Chef Michelle Bernstein is a COSENTYX® (secukinumab) patient and has been compensated for her time. Continue reading for Important Safety Information and a link to the full Prescribing ...

Novartis has come up short in its bid to expand its blockbuster drug Cosentyx to an autoimmune disease whose only biologic treatment options are an old Roche drug and the biosimilars that have ...

Atopic dermatitis and psoriasis are well-established battlefields for anti-inflammatory biologic drugs. Now, two drugmakers are preparing to launch products in a lesser-known disease area with ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet the primary endpoint of sustained remission at week 52 for a new indication ...

Novartis (NYSE:NVS) is throwing in the towel on a phase 3 program to gain an additional approval for its blockbuster Cosentyx (secukinumab) for active peripheral spondyloarthritis. The change in plans ...